• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.

作者信息

Matera M G, Caputi M, Cazzola M

机构信息

Institute of Pharmacology and Toxicology, Cardarelli Hospital, Naples, Italy.

出版信息

Respir Med. 1996 Sep;90(8):497-9. doi: 10.1016/s0954-6111(96)90178-x.

DOI:10.1016/s0954-6111(96)90178-x
PMID:8869445
Abstract
摘要

相似文献

1
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.对于慢性阻塞性肺疾病患者，临床推荐剂量的沙美特罗与异丙托溴铵联合使用并不比单独使用沙美特罗更有效。
Respir Med. 1996 Sep;90(8):497-9. doi: 10.1016/s0954-6111(96)90178-x.
2
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.长效吸入型β2肾上腺素能激动剂昔萘酸沙美特罗在慢性阻塞性肺疾病患者中的应用。
Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92. doi: 10.1164/ajrccm.163.5.9903053.
3
Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.吸入用沙美特罗：其在慢性阻塞性肺疾病中疗效的综述
Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006.
4
Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease.
Respir Med. 1998 Sep;92(9):1116-21. doi: 10.1016/s0954-6111(98)90404-8.
5
Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium.沙美特罗长期治疗慢性阻塞性肺疾病及异丙托溴铵的附加作用。
Eur Respir J. 2000 May;15(5):878-85. doi: 10.1034/j.1399-3003.2000.15e11.x.
6
Tiotropium step-up therapy in asthma.噻托溴铵在哮喘中的逐步升级治疗。
N Engl J Med. 2011 Feb 10;364(6):578; author reply 578-9. doi: 10.1056/NEJMc1013636.
7
Does salmeterol increase mortality in patients with COPD?沙美特罗会增加慢性阻塞性肺疾病患者的死亡率吗？
Cleve Clin J Med. 2001 Jul;68(7):600-1. doi: 10.3949/ccjm.68.7.600.
8
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Chest. 1996 Jan;109(1):294. doi: 10.1378/chest.109.1.294.
9
Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease.添加抗胆碱能溶液可延长慢性阻塞性肺疾病患者β2激动剂的支气管扩张作用。
Am J Med. 1996 Jan 29;100(1A):40S-48S. doi: 10.1016/s0002-9343(96)80073-8.
10
A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease.沙美特罗与氧托溴铵对稳定期慢性阻塞性肺疾病的支气管扩张作用比较
Respir Med. 1998 Feb;92(2):354-7. doi: 10.1016/s0954-6111(98)90121-4.

引用本文的文献

1
The efficacy and safety of additional treatment with short-acting muscarinic antagonist combined with long-acting beta-2 agonist in stable patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis.长效β2受体激动剂联合短效毒蕈碱拮抗剂对稳定期慢性阻塞性肺疾病患者的附加治疗效果及安全性：一项系统评价与荟萃分析
Chron Respir Dis. 2023 Jan-Dec;20:14799731231166008. doi: 10.1177/14799731231166008.
2
Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?吸入性抗胆碱能药物与β2肾上腺素能受体激动剂联合治疗慢性阻塞性肺疾病是否合理？
Drugs Aging. 2007;24(8):615-28. doi: 10.2165/00002512-200724080-00001.
3
Ipratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary disease.
异丙托溴铵与长效β2受体激动剂治疗稳定期慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD006101. doi: 10.1002/14651858.CD006101.
4
Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease.长效β2受体激动剂用于可逆性差的慢性阻塞性肺疾病
Cochrane Database Syst Rev. 2006 Jul 19;2006(3):CD001104. doi: 10.1002/14651858.CD001104.pub2.
5
Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.异丙托溴铵与短效β2受体激动剂治疗稳定期慢性阻塞性肺疾病的比较
Cochrane Database Syst Rev. 2006 Apr 19;2006(2):CD001387. doi: 10.1002/14651858.CD001387.pub2.
6
Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease.抗胆碱能支气管扩张剂与β2-拟交感神经药治疗慢性阻塞性肺疾病急性加重期的比较
Cochrane Database Syst Rev. 2002;2003(4):CD003900. doi: 10.1002/14651858.CD003900.
7
Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.吸入用沙美特罗：其在慢性阻塞性肺疾病中疗效的综述
Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006.
8
Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.吸入性短效β2受体激动剂与异丙托溴铵治疗慢性阻塞性肺疾病急性加重期的疗效比较
Cochrane Database Syst Rev. 2001;2001(2):CD002984. doi: 10.1002/14651858.CD002984.
9
Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.长效β2受体激动剂在稳定期慢性阻塞性肺疾病管理中的应用
Drugs. 2000 Aug;60(2):307-20. doi: 10.2165/00003495-200060020-00005.
10
Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease.沙美特罗单次常规剂量预处理对慢性阻塞性肺疾病患者溴化氧托品剂量-反应曲线的急性影响
Thorax. 1999 Dec;54(12):1083-6. doi: 10.1136/thx.54.12.1083.